Shari Rozen, MD
Family Medicine · Pittsburgh, PANPI 1356393987
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 53.7% of the total. Reporting peaked in 2023 at $1,051 and has fallen 64.2% since, to $376 in 2025.
Across 234 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$490
- GSK$281
- Pfizer$179
- Bayer$161
- Abbott$86
- plus $420 from 13 others
Across 501 payments — averaging $5841.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.4M
- GSK$1.1M
- AstraZeneca$205K
- AbbVie$110K
- Adaptive Biotechnologies Corporation$44K
- Sanofi US Services Inc.$38K
- plus $32K from 1 others
What the payments were for
- Food & beverage$3,488100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 131 | $1,872 |
| Novo Nordisk | 34 | $490 |
| GSK | 19 | $281 |
| Pfizer | 19 | $179 |
| Bayer | 5 | $161 |
| Abbott | 4 | $86 |
| Amgen | 4 | $72 |
| Lilly USA, LLC | 4 | $61 |
| Upsher-smith Laboratories LLC | 2 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Edwards Lifesciences | 1 | $33 |
| UCB, Inc. | 1 | $24 |
| Novartis | 2 | $23 |
| Lundbeck LLC | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
$3,488 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 157 | $154,863 |
| TrulicityDulaglutide | 97 | $104,696 |
| OzempicSemaglutide | 86 | $101,064 |
| JardianceEmpagliflozin | 57 | $76,741 |
| FarxigaDapagliflozin Propanediol | 46 | $56,260 |
| InvokanaCanagliflozin | 26 | $34,837 |
| MounjaroTirzepatide | 21 | $25,147 |
| XareltoRivaroxaban | 26 | $23,997 |
| RybelsusSemaglutide | 12 | $22,384 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 41 | $18,168 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $16,467 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 59 | $13,052 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $10,771 |
| Spiriva RespimatTiotropium Bromide | 13 | $10,538 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $10,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $179 | $154,863157 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $61 | $129,842118 claims |
| Novo NordiskOzempic, Rybelsus | $490 | $123,44898 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $20 | $87,28070 claims |
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta | $281 | $40,29099 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Pittsburgh
- Nathan BennettPittsburgh$465K
- Deborah GilboaPittsburgh$60K
- Gregory JaffePittsburgh$38K
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.